Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
136-150 of 4068 results
Matinas starts dosing in phase 1 study of orally administered aminoglycoside antibiotic MAT2501
Matinas BioPharma has commenced dosing in the Phase 1 clinical study of its lead antibiotic product candidate MAT2501, under development for the treatment of nontuberculous mycobacterium infections (NTM) as an initial indication.
Contract Research & Services > Clinical Trials > News
Pfizer's Bosulif found superior to Gleevec in phase 3 study in type of leukemia
By PBR Staff Writer
Pfizer’s cancer drug Bosulif (bosutinib) was found superior to Novartis' Gleevec (imatinib mesylate) in a phase 3 study for first-line treatment of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
Contract Research & Services > Clinical Trials > News
Shire's VONVENDI meets primary endpoint in controlling bleeding in VWD adults in phase 3 study
A phase 3 clinical trial of Shire's VONVENDI [von Willebrand factor (Recombinant)] to treat bleeds in elective surgical settings for adults with severe von Willebrand disease (VWD) has met primary endpoint.
Contract Research & Services > Clinical Trials > News
Pfizer’s Glasdegib improves OS in AML and MDS patients in phase 2 trial
The new phase 2 results demonstrated that Pfizer's investigational compound Glasdegib improved overall survival (OS) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Contract Research & Services > Clinical Trials > News
ACADIA begins phase 2 trial of Nuplazid in major depressive disorder
ACADIA Pharmaceuticals has started a Phase II study dubbed CLARITY to evaluate pimavanserin for adjunctive treatment in patients with major depressive disorder (MDD) who have an inadequate response to first-line therapies for clinical depression.
Contract Research & Services > Clinical Trials > News
Pfizer's Herceptin biosimilar succeeds in breast cancer study
By PBR Staff Writer
A clinical trial comparing the safety and efficacy of Pfizer's biosimilar PF-05280014 to Roche's Herceptin met the primary endpoint in a breast cancer trial.
Contract Research & Services > Clinical Trials > News
Recro Pharma's IV meloxicam meets primary endpoint in phase 3 trial
Recro Pharma has unveiled positive results from its second of two Phase III clinical trials assessing intravenous (IV) meloxicam for the treatment of acute postoperative pain.
Contract Research & Services > Clinical Trials > News
GSK starts phase III studies of daprodustat for anaemia
By PBR Staff Writer
GlaxoSmithKline (GSK) has started phase III development program with daprodustat for anaemia associated with chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Bavarian completes enrollment of phase 3 non-inferiority study of IMVAMUNE smallpox vaccine
Bavarian Nordic has completed enrollment of a Phase 3 clinical study designed to demonstrate non-inferiority between its investigational, non-replicating smallpox vaccine, IMVAMUNE and ACAM2000, the current U.S. licensed, and replicating smallpox vaccine.
Contract Research & Services > Clinical Trials > News
Juno Therapeutics places leukemia drug trial on clinical hold
Juno Therapeutics has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial.
Contract Research & Services > Clinical Trials > News
GSK's EGPA treatment meets endpoints in phase lll study
By PBR Staff Writer
A phase lll study of GlaxoSmithKline's mepolizumab has met its co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Contract Research & Services > Clinical Trials > News
Eli Lilly’s Alzheimer's drug fails in phase 3 trial
Eli Lilly and Company said that its solanezumab monoclonal antibody designed to treat dimentia associated with Alzheimer’s disease (AD) did not meet its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News
FDA lifts partial clinical hold on AstraZeneca head and neck cancer trials
By PBR Staff Writer
AstraZeneca has restarted recruiting patients into two large clinical trials on head and neck cancer that had been paused over bleeding concerns.
Contract Research & Services > Clinical Trials > News
Diurnal doses first patient in native oral testosterone formulation phase I trial
Diurnal Group has dosed the first patient in its native oral testosterone formulation (DITEST) Phase I clinical trial.
Contract Research & Services > Clinical Trials > News
Stealth BioTherapeutics’ elamipretide infusion improves kidney microvasculature in phase 2 trial
By PBR Staff Writer
A single dose of Stealth BioTherapeutics’ elamipretide drug prior to renal artery angioplasty and stenting procedures enhanced kidney function and blood flow for three months post-procedure in a phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
136-150 of 4068 results